Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging

Fichna, Jakub; Janecka, Anna

doi:10.1021/bc025542f

Cited by 130 publications

(107 citation statements)

References 108 publications

(159 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Os radiofármacos específicos são direcionados por moléculas biologicamente ativas, como, por exemplo, anticorpos e peptídeos, que se ligam a receptores celulares ou são transportados para o interior de determinadas célu-las. A capacidade da biomolécula reconhecer os receptores vai determinar a fixação do radiofármaco no tecido pretendido e não deverá ser alterada com a incorporação do radionuclídeo (Jurisson et al, 1993;Fichna et al, 2003).…”

Section: Tabela II -Geradores Utilizados Em Medicina Nuclearunclassified

See 1 more Smart Citation

Preparações radiofarmacêuticas e suas aplicações

Oliveira¹,

Santos²,

Ferreira³

et al. 2006

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

Section: Tabela II -Geradores Utilizados Em Medicina Nuclearunclassified

“…A Tabela V apresenta radiofármacos específicos usados em diagnóstico e as suas aplicações (Dilworth et al, 1998;Liu et al, 1999;Jurisson et al, 1999;Vallabhajosula, 2001;Johannsen, 2001;Fichna et al, 2003).…”

Section: Tabela II -Geradores Utilizados Em Medicina Nuclearunclassified

Preparações radiofarmacêuticas e suas aplicações

Oliveira¹,

Santos²,

Ferreira³

et al. 2006

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

“…Acyclic BCAs, such as ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), desferrioxamine (DFO), N,N'-di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED), and their derivatives, have been used for labeling macromolecules with 111 In, 67/ 68 Ga, or 90 Y for tumor imaging and therapy [19][20][21][22]. However, most of these complexes have low in vivo and in vitro stabilities due to their tendency to undergo acid-or cation-promoted dissociation [23,24].…”

Section: Introductionmentioning

confidence: 99%

68Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography

Shetty

Lee

Jeong

2010

Nucl Med Mol Imaging

View full text Add to dashboard Cite

68 Ga is a promising emerging radionuclide for positron emission tomography (PET). It is produced using a 68 Ge/ 68 Ga-generator, and thus, would enable the cyclotronindependent distribution of PET. However, new 68 Galabeled radiopharmaceuticals that can replace 18 F-labeled agents like [ 18 F]fluorodeoxyglucose (FDG) are needed. Most of the 68 Ga-labeled derivatives currently used are peptide agents, but the developments of other agents, such as amino acid derivatives, nitroimidazole derivatives, and glycosylated human serum albumin, are being actively pursued in many laboratories. Thus, appearance of new 68 Ga-labeled radiopharmaceuticals with high impact are expected in the near future. Here, we present an overview of 68 Ga-labeled agents in terms of their clinical significances and relevances to the management of certain tumors, and pertinent pre-clinical developments.

show abstract

“…O seu uso, também, foi muito facilitado com o desenvolvimento de geradores molibdênio-99/tecnécio-99m e a formulação de kits liofilizados, tornando o seu uso uma realidade em radiofarmácia hospitalar (Banerjee et al, 2001;Faintuch, et al, 2005). Em 2002, era usado em quase 85% dos exames de imagem diagnóstica cintilográficas realizados por ano (Jurisson, 2002;Fichna et al, 2003).…”

Section: Introductionunclassified